Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 109 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR NHS ‘understaffed and underequipped’ to tackle cancer, say 3 in 4... May 25, 2022 No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... September 9, 2021 Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers February 3, 2026 FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple... July 14, 2021 Load more HOT NEWS The Mediterranean Diet Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive... Celebrating 75 years of NHS cancer care Genetic discovery could guide treatment for aggressive childhood cancer
